Abstract
To assess the consequence of second BMT (BMT2) for leukemia relapse after allogeneic BMT, we analyzed the clinical course of 66 recipients who were treated by BMT2 in Japan. Diagnoses included 29 ANLL, 27 ALL, six CML and four MDS. Durations between the first BMT (BMT1) to relapse and BMT1 to BMT2 were 13.5 ± 13.7 months and 17.4 ± 13.9 months, respectively. Donors for BMT2 were replaced in 11 cases. Thirty-one patients were in CR (or CP) at BMT2. Earlier deaths were observed in those who received BMT2 within 12 months after BMT1, mostly caused by regimen-related toxicity and infections. Overall leukemia-free survival rate was 28% at 2 years and 16% at 4 years. Factors influencing the poor prognosis after BMT2 were early (<6 months) relapse, early (<12 months) bmt2, not in remission at bmt2, and all. intensified conditioning did not affect either remission duration or lfs. among the 39 cases observed for more than 100 days, 18 developed chronic gvhd (cgvhd) and showed longer remission duration than those without cgvhd. our analysis indicates that bmt2 as treatment for leukemia relapse is effective in selected cases, and exploration of pre-bmt treatment and post-bmt immunotherapy is warranted.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Kishi, K., Takahashi, S., Gondo, H. et al. Second allogeneic bone marrow transplantation for post-transplant leukemia relapse: results of a survey of 66 cases in 24 Japanese institutes. Bone Marrow Transplant 19, 461–466 (1997). https://doi.org/10.1038/sj.bmt.1700680
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/sj.bmt.1700680
Keywords
This article is cited by
-
Outcomes in patients with acute lymphoblastic leukemia who underwent second allogeneic hematopoietic cell transplantation for relapse after first transplantation
International Journal of Hematology (2022)
-
Outcome predictors after retransplantation in relapsed acute lymphoblastic leukemia: a multicenter, retrospective study
Annals of Hematology (2021)
-
Second unmanipulated allogeneic transplantation could be used as a salvage option for patients with relapsed acute leukemia post-chemotherapy plus modified donor lymphocyte infusion
Frontiers of Medicine (2021)
-
Second allogeneic transplants for multiple myeloma: a report from the EBMT Chronic Malignancies Working Party
Bone Marrow Transplantation (2021)
-
Geriatric nutritional risk index as a useful prognostic factor in second allogeneic hematopoietic stem cell transplantation
Annals of Hematology (2020)